Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide

Archivum Immunologiae et Therapiae Experimentalis

Volumn 45, Issue 1, 1997, Pages 79-85

  Kuśnierczyk, Halina ^a   Konarski, Leszek ^a   Kowalski, Przemyslaw ^b   Radzikowski, Czesław ^a  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

bromofosfamides; ifosfamide; mesna uroprotection; urotoxicity

Indexed keywords

BROMOFOSFAMIDE DERIVATIVE; CBM 11; CBM 4A; CHLOROBROMOFOSFAMIDE; IFOSFAMIDE; MESNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; INTRAPERITONEAL DRUG ADMINISTRATION; ISOMERISM; MOUSE; NONHUMAN; TOXICITY TESTING; URINARY TRACT DISEASE;

ADMINISTRATION, ORAL; ANIMALS; CYSTITIS; EDEMA; FEMALE; HEMORRHAGE; IFOSFAMIDE; INJECTIONS, INTRAPERITONEAL; LETHAL DOSE 50; MAXIMUM ALLOWABLE CONCENTRATION; MESNA; MICE; MICE, INBRED BALB C; MICE, INBRED DBA; NECROSIS; STEREOISOMERISM; URINARY BLADDER;

EID: 0030947147     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. BRADE W., SEEBER S. and HERDRICH K. (1986): Comparative activity of ifosfamide and cyclophosphamide. Cancer Chemother. Pharmacol., 18 (suppl. 2), 1-9.
2. BREMMER D. N., McCORMICK J. S. C. and THOMSON J. W. (1974): Clinical trial of isophosphamide (NSC-109724) - results and side effects. Cancer Chemother. Rep., 58, 889-893.
3. BROCK N. (1989): Oxazaphosphorine cytostatics: past-present-future. Cancer Res., 49, 1-7.
4. BROCK N. and POHL J. (1983): The development of mesna for regional detoxification. Cancer Treat. Rev., 10 (suppl. A), 33-43.
5. BROCK N. and POHL J. (1987): The basis of modern ifosfamide therapy. In BRADE W. P., NAGEL G. A. and SEEBER S. (eds.): Ifosfamide in tumor therapy. Karger, Basel, 1-11.
6. BROCK N., POHL J. and STEKAR L. (1981): Studies on urotoxicity of oxazaphosphorine cytostatics and its prevention. I. Experimental studies on the urotoxicity of alkylating compounds. Eur. J. Cancer, 17 (6), 595-607.
7. BROCK N., POHL J. and STEKAR L. (1981): Studies on urotoxicity of oxazaphosphorine cytostatics and its prevention. II. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds. Eur. J. Cancer Clin. Oncol., 17 (11), 1155-1163.
8. BROCK N., POHL J., STEKAR L. and SCHEEF W, (1982): Studies on urotoxicity of oxazaphosphorine cytostatics and its prevention. III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur. J. Cancer Clin. Oncol., 18 (12), 1377-1387
9. BURKERT H. (1983): Clinical overview of mesna. Cancer Treat Rev., 10 (suppl. A), 175-178.
10. DRINGS P. (1977): Clinical experience with Holoxan. In BURKERT H. and VOIGT H. C. (eds.): International Holoxan-Symposium, Düsseldorf 21-23.03.1977. Asta-Werke AG Chemische Fabrik, Bielefeld/Germany, 104-107.
11. FALKSON G., VAN DYK J. J., STAPELBERG R. and FALKSON H. C. (1982): Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment. Cancer Chemother. Pharmacol., 9, 81-84.
12. FICHTNER I. and NOWAK C. (1987): Pharmacological and toxicological effects of ifosfamide (Holoxan®) combined with mesna romitexan®) in different murine tumor models. In BRADE W. P., NAGEL G. A. and SEEBER S. (eds.): Ifosfamide in tumor therapy. Karger, Basel, 93-104.
13. GLAZMAN-KUŚNIERCZYK H., MATUSZYK J. and RADZIKOWSKI C. (1992): Antitumor activity evaluation of bromine-substituted analogues of ifosfamide. I. Stereodifferentiation of biological effects and selection of the most potent compounds. Immunopharmacol. Immunotoxicol., 14 (4), 883-911.
14. GOLDIN A., VENDITI J. M. and KLINE I. (1977): Preclinical investigation with ifosfamide in relation to cyclophosphamide. In BURKERT H. and VOIGT H. C. (eds.): International Holoxan-Symposium, Düsseldorf, 21-23.03.1977. Asta-Werke AG Chemische Fabrik, Bielefeld/Germany, 19-28.
15. HENEY D., WHEELDON J., RUSHWORTH P., CHAPMAN C., LEWIS I. J. and BAILEY C. C. (1991): Progressive renal toxicity due to ifosfamide. Arch. Dis. Child., 55, 966-970.
16. MONDORF A. W., WUST G., DRINGS P., KLINGEN A. and FALKENBERG F. W. (1987): Kidney tolerance of ifosfamide in combination with mesna after single-dose infusion and 5-day dose fractionation. In BRADE W. P., NAGEL G. A. and SEEBER S. (eds.): Ifosfamide in tumor therapy. Karger, Basel, 84-93.
17. SCHEEF W. and HOEFER-JANKER H. (1977): Clinical experience with Holoxan. In BURKET H. and VOIGT H. C. (eds.): International Holoxan-Symposium, Düsseldorf, 21-23.03.1997. ta-Werke AG Chemische Fabrik, Bielefed/Germany, 99-103.
18. SKINNER R., PEARSON A. D. J., PRICE L., COULTHART M. G. and CRAFT A. W. (1990): Nephrotoxicity after ifosfamide. Arch. Dis. Child., 65, 732-738.
19. SLADEK N. A. (1988): Metabolism of oxazaphosphorines. Pharmacol. Ther., 37, 301-355.
20. STEC W. J. (1980): Chiral anticancer oxazaphosphorinanes - stereospecific synthesis, configurational assignments and biological evaluations. In STEC W. J. (ed.:) Phosphorus chemistry directed towards biology. Pergamon Press, 95-108.
21. VAN DYK J. J., FALKSON H. C., VAN DER MERWE A. M. and FALKSON G. (1972): Unexpected toxicity in patients treated with iphosphamide. Cancer Res., 32, 921-924.
22. WAGNER T. and DRINGS P. (1987): Pharmacokinetics and bioavailability of oral ifosfamide. In BRADE W. P., NAGEL G. A. and SEEBER S. (eds): Ifosfamide in tumor therapy, Karger, Basel, 53-60.
23. ZALUPSKI M. and BAKER L. H. (1988): Ifosfamide (review). J. Nat. Cancer Inst., 80, 556-566.